SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Nicolas Morin, Marc Morissette, Laurent Grégoire, Thérèse Di Paolo, Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 27

    CrossRef

  2. 2
    Fernando Eduardo Padovan-Neto, Roberta Cavalcanti-Kiwiatkoviski, Ruither Oliveira Gomes Carolino, Janete Anselmo-Franci, Elaine Del Bel, Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats, Neuropharmacology, 2015, 89, 87

    CrossRef

  3. 3
    P. Svenningsson, C. Rosenblad, K. af Edholm Arvidsson, K. Wictorin, C. Keywood, B. Shankar, D. A. Lowe, A. Bjorklund, H. Widner, Eltoprazine counteracts L-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study, Brain, 2015, 138, 4, 963

    CrossRef

  4. 4
    Manuela Pilleri, Angelo Antonini, Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease, Expert Opinion on Drug Safety, 2015, 14, 2, 281

    CrossRef

  5. 5
    Garikoitz Azkona, Ainhoa Sagarduy, Asier Aristieta, Nerea Vazquez, Verónica Zubillaga, José Angel Ruíz-Ortega, Esther Pérez-Navarro, Luisa Ugedo, Rosario Sánchez-Pernaute, Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in l-DOPA-treated rats, Neuropharmacology, 2014, 79, 726

    CrossRef

  6. 6
    Melissa M. Conti, Corinne Y. Ostock, David Lindenbach, Adam A. Goldenberg, Elias Kampton, Rich Dell'isola, Aaron C. Katzman, Christopher Bishop, Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats, Neuropharmacology, 2014, 77, 1

    CrossRef

  7. 7
    Nicolas Morin, Vincent A. Jourdain, Thérèse Di Paolo, Modeling dyskinesia in animal models of Parkinson disease, Experimental Neurology, 2014, 256, 105

    CrossRef

  8. 8
    Marios Politis, Kit Wu, Clare Loane, David J. Brooks, Lorenzo Kiferle, Federico E. Turkheimer, Peter Bain, Sophie Molloy, Paola Piccini, Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients, Journal of Clinical Investigation, 2014, 124, 3, 1340

    CrossRef

  9. 9
    N. Nevalainen, S. af Bjerkén, G.A. Gerhardt, I. Strömberg, Serotonergic nerve fibers in l-DOPA-derived dopamine release and dyskinesia, Neuroscience, 2014, 260, 73

    CrossRef

  10. 10
    Elisabetta Tronci, Manolo Carta, 5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation, Basal Ganglia, 2013, 3, 1, 9

    CrossRef

  11. 11
    Hua Wang, Xin-Yi Chen, Wen-Fang Chen, Yan Xue, Lei Wei, Lei Chen, Anticataleptic effects of 5-HT1B receptors in the globus pallidus, Neuroscience Research, 2013, 77, 3, 162

    CrossRef

  12. 12
    Kristin B. Dupre, Corinne Y. Ostock, Jessica A. George, Karen L. Eskow Jaunarajs, Cara M. Hueston, Christopher Bishop, Effects of 5-HT1AReceptor Stimulation on D1 Receptor Agonist-Induced Striatonigral Activity and Dyskinesia in Hemiparkinsonian Rats, ACS Chemical Neuroscience, 2013, 4, 5, 747

    CrossRef

  13. 13
    Margarita Valhondo, Isabel Marco, Mar Martín-Fontecha, Henar Vázquez-Villa, José A. Ramos, Reinhard Berkels, Thomas Lauterbach, Bellinda Benhamú, María L. López-Rodríguez, New Serotonin 5-HT1AReceptor Agonists Endowed with Antinociceptive Activityin Vivo, Journal of Medicinal Chemistry, 2013, 56, 20, 7851

    CrossRef

  14. 14
    James B. Koprich, Philippe Huot, Susan H. Fox, Keith Jarvie, Anthony E. Lang, Philip Seeman, Jonathan M. Brotchie, The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 43, 151

    CrossRef

  15. 15
    Philippe Huot, Susan H. Fox, The serotonergic system in motor and non-motor manifestations of Parkinson’s disease, Experimental Brain Research, 2013, 230, 4, 463

    CrossRef

  16. 16
    C. Loane, M. Politis, Buspirone: What is it all about?, Brain Research, 2012, 1461, 111

    CrossRef

  17. 17
    Golnasim Riahi, Marc Morissette, Daniel Lévesque, Claude Rouillard, Pershia Samadi, Martin Parent, Thérèse Di Paolo, Effect of chronic l-DOPA treatment on 5-HT1A receptors in parkinsonian monkey brain, Neurochemistry International, 2012, 61, 7, 1160

    CrossRef

  18. 18
    John Seibyl, David Russell, Danna Jennings, Kenneth Marek, Neuroimaging Over the Course of Parkinson's Disease: From Early Detection of the At-Risk Patient to Improving Pharmacotherapy of Later-Stage Disease, Seminars in Nuclear Medicine, 2012, 42, 6, 406

    CrossRef

  19. 19
    Yoland Smith, Thomas Wichmann, Stewart A Factor, Mahlon R DeLong, Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa, Neuropsychopharmacology, 2012, 37, 1, 213

    CrossRef

  20. 20
    Philippe Huot, Tom H. Johnston, James B. Koprich, Lieke Winkelmolen, Susan H. Fox, Jonathan M. Brotchie, Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque, Neurobiology of Aging, 2012, 33, 1, 207.e9

    CrossRef

  21. 21
    Eunju Shin, Joanna Garcia, Christian Winkler, Anders Björklund, Manolo Carta, Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease, Neurobiology of Disease, 2012, 47, 3, 393

    CrossRef

  22. 22
    Perdita A. Cheshire, David R. Williams, Serotonergic involvement in levodopa-induced dyskinesias in Parkinson’s disease, Journal of Clinical Neuroscience, 2012, 19, 3, 343

    CrossRef

  23. 23
    Christopher Bishop, Jessica A. George, William Buchta, Adam A. Goldenberg, Mohamed Mohamed, Sando O. Dickinson, Satie Eissa, Karen L. Eskow Jaunarajs, Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats, European Journal of Neuroscience, 2012, 36, 6
  24. 24
    P. De Deurwaerdère, S. Navailles, What can we expect from the serotonergic side of l-DOPA?, Revue Neurologique, 2012, 168, 12, 927

    CrossRef

  25. 25
    Xiaoqun Zhang, Martin Egeland, Per Svenningsson, Antidepressant-like properties of sarizotan in experimental Parkinsonism, Psychopharmacology, 2011, 218, 4, 621

    CrossRef

  26. 26
    Javad Mahmoudi, Alireza Mohajjel Nayebi, Morteza Samini, Siamak Reyhani-Rad, Vahab Babapour, Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats, Pharmacological Reports, 2011, 63, 4, 908

    CrossRef

  27. 27
    Nina Nevalainen, Sara af Bjerkén, Martin Lundblad, Greg A. Gerhardt, Ingrid Strömberg, Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia, Journal of Neurochemistry, 2011, 118, 1
  28. 28
    Kristin B. Dupre, Corinne Y. Ostock, Karen L. Eskow Jaunarajs, Thomas Button, Lisa M. Savage, William Wolf, Christopher Bishop, Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats, Experimental Neurology, 2011, 229, 2, 288

    CrossRef

  29. 29
    Isabel Marco, Margarita Valhondo, Mar Martı́n-Fontecha, Henar Vázquez-Villa, Joaquı́n Del Rı́o, Anna Planas, Onintza Sagredo, José A. Ramos, Iván R. Torrecillas, Leonardo Pardo, Diana Frechilla, Bellinda Benhamú, Marı́a L. López-Rodrı́guez, New Serotonin 5-HT1AReceptor Agonists with Neuroprotective Effect against Ischemic Cell Damage, Journal of Medicinal Chemistry, 2011, 54, 23, 7986

    CrossRef

  30. 30
    Livia Dézsi, László Vécsei, Parkinson’s disease: will therapy move beyond dopaminergic medication?, Clinical Investigation, 2011, 1, 3, 381

    CrossRef

  31. 31
    Suk J. Gil, Chang H. Park, Jeong E. Lee, Yang K. Minn, Hyun C. Koh, Positive association between striatal serotonin level and abnormal involuntary movements in chronic l-DOPA-treated hemiparkinsonian rats, Brain Research Bulletin, 2011, 84, 2, 151

    CrossRef

  32. 32
    Manfred Gerlach, Gerd D. Bartoszyk, Peter Riederer, Olivia Dean, Maarten van den Buuse, Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease, Journal of Neural Transmission, 2011, 118, 12, 1733

    CrossRef

  33. 33
    Corinne Y. Ostock, Kristin B. Dupre, Karen L. Eskow Jaunarajs, Hannah Walters, Jessica George, David Krolewski, Paul D. Walker, Christopher Bishop, Role of the primary motor cortex in l-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation, Neuropharmacology, 2011, 61, 4, 753

    CrossRef

  34. 34
    Philippe Huot, Susan H. Fox, Jonathan M. Brotchie, The serotonergic system in Parkinson's disease, Progress in Neurobiology, 2011, 95, 2, 163

    CrossRef

  35. 35
    Tom H. Johnston, Emma L. Lane, Pathophysiology, Pharmacology, and Biochemistry of Dyskinesia, 2011,

    CrossRef

  36. 36
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  37. 37
    Shu-Jing Zhang, Hua Wang, Yan Xue, Wing-Ho Yung, Lei Chen, Behavioral and electrophysiological effects of 5-HT in globus pallidus of 6-hydroxydopamine lesioned rats, Journal of Neuroscience Research, 2010, 88, 7
  38. 38
    Alireza M. Nayebi, Siyamak R. Rad, Mehdi Saberian, Saeid Azimzadeh, Morteza Samini, Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT1A receptors in rats, Pharmacological Reports, 2010, 62, 2, 258

    CrossRef

  39. 39
    Juliana Bronzova, Cristina Sampaio, Robert A. Hauser, Anthony E. Lang, Olivier Rascol, Ad Theeuwes, Serge V. van de Witte, Guus van Scharrenburg, Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease, Movement Disorders, 2010, 25, 6
  40. 40
    Yoshihiro Tani, Atsuto Ogata, Makoto Koyama, Teruyoshi Inoue, Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats, European Journal of Pharmacology, 2010, 649, 1-3, 218

    CrossRef

  41. 41
    Mark J. Millan, From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease, Pharmacology & Therapeutics, 2010, 128, 2, 229

    CrossRef

  42. 42
    Kerstin Buck, Boris Ferger, l-DOPA-induced dyskinesia in Parkinson's disease: a drug discovery perspective, Drug Discovery Today, 2010, 15, 19-20, 867

    CrossRef

  43. 43
    Elisabeth Wolf, Klaus Seppi, Regina Katzenschlager, Guenter Hochschorner, Gerhard Ransmayr, Petra Schwingenschuh, Erwin Ott, Iris Kloiber, Dietrich Haubenberger, Eduard Auff, Werner Poewe, Long-term antidyskinetic efficacy of amantadine in Parkinson's disease, Movement Disorders, 2010, 25, 10
  44. 44
    Manolo Carta, Thomas Carlsson, Ana Muñoz, Deniz Kirik, Anders Björklund, Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease, Movement Disorders, 2010, 25, S1
  45. 45
    Sukju Gil, Changhwan Park, Jeongeun Lee, Hyunchul Koh, The Roles of Striatal Serotonin and l-Amino-acid Decarboxylase on l-DOPA-induced Dyskinesia in a Hemiparkinsonian Rat Model, Cellular and Molecular Neurobiology, 2010, 30, 6, 817

    CrossRef

  46. 46
    Alessandro Stefani, Mariangela Pierantozzi, Giacomo Koch, Salvatore Galati, Paolo Stanzione, Therapy for dyskinesias in Parkinson’s disease patients, Future Neurology, 2010, 5, 2, 277

    CrossRef

  47. 47
    Emma Louise Lane, Patrik Brundin, M. Angela Cenci, Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease, Neurobiology of Disease, 2009, 35, 1, 42

    CrossRef

  48. 48
    Martin Lundblad, Sara Af Bjerkén, M. Angela Cenci, Francois Pomerleau, Greg A. Gerhardt, Ingrid Strömberg, Chronic intermittent L-DOPA treatment induces changes in dopamine release, Journal of Neurochemistry, 2009, 108, 4
  49. 49
    C. Marin, E. Aguilar, M. C. Rodríguez-Oroz, G. D. Bartoszyk, J. A. Obeso, Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats, Psychopharmacology, 2009, 204, 2, 241

    CrossRef

  50. 50
    Laurent Grégoire, Pershia Samadi, Julie Graham, Paul J. Bédard, Gerd D. Bartoszyk, Thérèse Di Paolo, Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys, Parkinsonism & Related Disorders, 2009, 15, 6, 445

    CrossRef

  51. 51
    F.E. Padovan-Neto, M.B. Echeverry, V. Tumas, E.A. Del-Bel, Nitric oxide synthase inhibition attenuates l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease, Neuroscience, 2009, 159, 3, 927

    CrossRef

  52. 52
    Susan H. Fox, Rosalind Chuang, Jonathan M. Brotchie, Serotonin and Parkinson's disease: On movement, mood, and madness, Movement Disorders, 2009, 24, 9
  53. 53
    Ana Muñoz, Thomas Carlsson, Elisabetta Tronci, Deniz Kirik, Anders Björklund, Manolo Carta, Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model, Experimental Neurology, 2009, 219, 1, 298

    CrossRef

  54. 54
    Dieter Scheller, Christoph Ullmer, Reinhard Berkels, Mirella Gwarek, Hermann Lübbert, The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease, Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 1, 73

    CrossRef

  55. 55
    Karen L. Eskow, Kristin B. Dupre, Christopher J. Barnum, Sando O. Dickinson, John Y. Park, Christopher Bishop, The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats, Synapse, 2009, 63, 7
  56. 56
    Emma Lane, Stephen Dunnett, Animal models of Parkinson’s disease and L-dopa induced dyskinesia: How close are we to the clinic?, Psychopharmacology, 2008, 199, 3, 303

    CrossRef

  57. 57
    Kristin B. Dupre, Karen L. Eskow, Aimee Steiniger, Anna Klioueva, Giselle E. Negron, Lydia Lormand, John Y. Park, Christopher Bishop, Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on l-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat, Psychopharmacology, 2008, 199, 1, 99

    CrossRef

  58. 58
    Peter Jenner, Functional models of Parkinson's disease: A valuable tool in the development of novel therapies, Annals of Neurology, 2008, 64, S2
  59. 59
    Susan H Fox, Jonathan M Brotchie, Anthony E Lang, Non-dopaminergic treatments in development for Parkinson's disease, The Lancet Neurology, 2008, 7, 10, 927

    CrossRef

  60. 60
    G. Linazasoro, N. Van Blercom, L. Ugedo, J. A. Ruiz Ortega, Pharmacological treatment of Parkinson’s disease: life beyond dopamine D2/D3 receptors?, Journal of Neural Transmission, 2008, 115, 3, 431

    CrossRef

  61. 61
    Peter Jenner, Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities, Movement Disorders, 2008, 23, S3
  62. 62
    Kristin B. Dupre, Karen L. Eskow, Christopher J. Barnum, Christopher Bishop, Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat, Neuropharmacology, 2008, 55, 8, 1321

    CrossRef

  63. 63
    Fabrizio Stocchi, Michele Tagliati, C. Warren Olanow, Treatment of levodopa-induced motor complications, Movement Disorders, 2008, 23, S3
  64. 64
    Graeme Watson, Paul Chazot, Drug-induced dyskinesias in Parkinson's disease: New surgical and pharmacotherapeutic approaches, Current Anaesthesia & Critical Care, 2007, 18, 1, 24

    CrossRef

  65. 65
    Andrzej Dekundy, Martin Lundblad, Wojciech Danysz, M. Angela Cenci, Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model, Behavioural Brain Research, 2007, 179, 1, 76

    CrossRef

  66. 66
    Laurence Mignon, William A. Wolf, Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson’s disease, Psychopharmacology, 2007, 192, 1, 49

    CrossRef

  67. 67
    Kristin B. Dupre, Karen L. Eskow, Giselle Negron, Christopher Bishop, The differential effects of 5-HT1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat, Brain Research, 2007, 1158, 135

    CrossRef

  68. 68
    Karen L. Eskow, Vikas Gupta, Salmahn Alam, John Y. Park, Christopher Bishop, The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy, Pharmacology Biochemistry and Behavior, 2007, 87, 3, 306

    CrossRef

  69. 69
    Y Naidu, K Ray Chaudhuri, Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson’s disease, Expert Opinion on Drug Delivery, 2007, 4, 2, 111

    CrossRef

  70. 70
    Carlo Colosimo, Giovanni Fabbrini, Alfredo Berardelli, Drug Insight: new drugs in development for Parkinson's disease, Nature Clinical Practice Neurology, 2006, 2, 11, 600

    CrossRef

  71. 71
    John C Morgan, Kapil D Sethi, Emerging drugs for Parkinson’s disease, Expert Opinion on Emerging Drugs, 2006, 11, 3, 403

    CrossRef

  72. 72
    Aloke K Dutta PhD, Weidong Le MD, PhD, Existing dopaminergic therapies for Parkinson’s disease, Expert Opinion on Therapeutic Patents, 2006, 16, 12, 1613

    CrossRef

  73. 73
    Jeffrey C. Glennon, Guus Van Scharrenburg, Eric Ronken, Mayke B. Hesselink, Jan-Hendrik Reinders, Martina Van Der Neut, Stephen K. Long, Rolf W. Feenstra, Andrew C. McCreary, In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): A novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist, Synapse, 2006, 60, 8
  74. 74
    C. Hofmann, U. Penner, R. Dorow, H. H. Pertz, S. J??hnichen, R. Horowski, K. P. Latt??, D. Palla, B. Schurad, Lisuride, a Dopamine Receptor Agonist With 5-HT2B Receptor Antagonist Properties, Clinical Neuropharmacology, 2006, 29, 2, 80

    CrossRef

  75. 75
    Christopher Bishop, Jennifer L. Taylor, Donald M. Kuhn, Karen L. Eskow, John Y. Park, Paul D. Walker, MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation, European Journal of Neuroscience, 2006, 23, 10
  76. 76
    Anthony H. V. Schapira, Erwan Bezard, Jonathan Brotchie, Frédéric Calon, Graham L. Collingridge, Borris Ferger, Bastian Hengerer, Etienne Hirsch, Peter Jenner, Nicolas Le Novère, José A. Obeso, Michael A. Schwarzschild, Umberto Spampinato, Giora Davidai, Novel pharmacological targets for the treatment of Parkinson's disease, Nature Reviews Drug Discovery, 2006, 5, 10, 845

    CrossRef

  77. 77
    Masahiro Nomoto, Masahiro Nagai, Pharmacological consideration of the symptoms resistant to dopaminergic therapy, Parkinsonism & Related Disorders, 2006, 12, S83

    CrossRef

  78. 78
    M. Angela Cenci, Martin Lundblad, Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia, Journal of Neurochemistry, 2006, 99, 2
  79. 79
    Jennifer L. Taylor, Christopher Bishop, Thomas Ullrich, Kenner C. Rice, Paul D. Walker, Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not l-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat, Neuropharmacology, 2006, 50, 6, 761

    CrossRef

  80. 80
    Susan H. Fox, Anthony E. Lang, Jonathan M. Brotchie, Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure, Movement Disorders, 2006, 21, 10
  81. 81
    Susan H. Fox, Jonathan M. Brotchie, Non-Dopaminergic Approaches to the Treatment of Parkinson's Disease,